AbFero Pharmaceuticals

Boston, United States Founded: 2016 • Age: 10 yrs
Oral iron chelators are developed for iron overload disease treatment.
Request Access

About AbFero Pharmaceuticals

AbFero Pharmaceuticals is a company based in Boston (United States) founded in 2016 by Raymond J Bergeron.. AbFero Pharmaceuticals has raised $1.78 million across 5 funding rounds from investors including Eureka Network and Cure Parkinson's. AbFero Pharmaceuticals offers products and services including SP-420. AbFero Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.

  • Headquarter Boston, United States
  • Founders Raymond J Bergeron
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Abfero Pharmaceuticals, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.78 M (USD)

    in 5 rounds

  • Latest Funding Round
    $500 K (USD), Seed

    Mar 22, 2021

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of AbFero Pharmaceuticals

AbFero Pharmaceuticals offers a comprehensive portfolio of products and services, including SP-420. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Lead candidate for treating iron overload and related conditions.

Funding Insights of AbFero Pharmaceuticals

AbFero Pharmaceuticals has successfully raised a total of $1.78M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $500 thousand completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Seed — $500,000
  • First Round

    (11 Apr 2019)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2021 Amount Seed - AbFero Pharmaceuticals Valuation

investors

Feb, 2021 Amount Grant - AbFero Pharmaceuticals Valuation

investors

Dec, 2020 Amount Seed - AbFero Pharmaceuticals Valuation Eureka
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in AbFero Pharmaceuticals

AbFero Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Eureka Network and Cure Parkinson's. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Business management consulting services are offered to clients.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by AbFero Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - AbFero Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Abfero Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of AbFero Pharmaceuticals

AbFero Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Developer of small molecule therapeutics for endocrine and CNS disorders
domain founded_year HQ Location
Small molecule drugs for rare diseases are developed.
domain founded_year HQ Location
Therapies for neurological and neuropsychiatric diseases are developed.
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Abfero Pharmaceuticals

Frequently Asked Questions about AbFero Pharmaceuticals

When was AbFero Pharmaceuticals founded?

AbFero Pharmaceuticals was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is AbFero Pharmaceuticals located?

AbFero Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Is AbFero Pharmaceuticals a funded company?

AbFero Pharmaceuticals is a funded company, having raised a total of $1.78M across 5 funding rounds to date.

What does AbFero Pharmaceuticals do?

AbFero Pharmaceuticals was founded in 2016 and is based in Boston, United States. Oral iron chelators are developed by the company within the biotechnology sector for addressing iron overload diseases. The lead candidate, SP-420, is designed as an oral treatment for genetic conditions leading to retinal and neurologic disorders, as well as other debilitating effects. Additional solutions are provided for age-related macular degeneration, Parkinsons disease, and traumatic brain injury.

Who are the top competitors of AbFero Pharmaceuticals?

AbFero Pharmaceuticals's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.

What products or services does AbFero Pharmaceuticals offer?

AbFero Pharmaceuticals offers SP-420.

Who are AbFero Pharmaceuticals's investors?

AbFero Pharmaceuticals has 2 investors. Key investors include Eureka Network, and Cure Parkinson's.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available